London and Cambridge-based CHARM Therapeutics, a biotechnology company specialising in precision oncology, has raised $80 million in an oversubscribed Series B financing round to advance its lead menin inhibitor programme into clinical development. The round was co-led by New Enterprise Associates (NEA) and SR One, with additional participation from existing investors OrbiMed, F-Prime Capital, Khosla... Read More














:max_bytes(150000):strip_icc()/HDC-GettyImages-668641904-9179dc9fe60446d8b4d8a08fbffcf46d.jpg?w=600&resize=600,400&ssl=1)





Recent Comments